{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:54:38Z","timestamp":1769115278518,"version":"3.49.0"},"reference-count":30,"publisher":"BMJ","issue":"13","funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Heart Lung Foundation"},{"name":"Stockholms County Council"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,12,22]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF) is common in patients with heart failure (HF), and oral anticoagulants (OAC) are indicated. The aim was to assess prevalence of, predictors of and consequences of OAC non-use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included patients with AF, HF and no previous valve replacement from the Swedish Heart Failure Registry. High and low CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc and HAS-BLED scores were defined as above\/below median. Multivariable logistic regressions were used to assess the associations between baseline characteristics and OAC use and between CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc and HAS-BLED scores and OAC use. Multivariable Cox regressions were used to assess associations between CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc and HAS-BLED scores, OAC use and two composite outcomes: all-cause death\/stroke and all-cause death\/major bleeding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 21\u2009865 patients, only 12\u2009659 (58%) received OAC. Selected predictors of OAC non-use were treatment with platelet inhibitors, less use of HF treatments, paroxysmal AF, history of bleeding, no previous stroke, planned follow-up in primary care, older age, living alone, lower income and variables associated with more severe HF. For each 1-unit increase in CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc and HAS-BLED, the ORs (95%\u2009CI) of OAC use were 1.24 (1.21\u20131.27) and 0.32 (0.30\u20130.33), and the HRs for death\/stroke were 1.08 (1.06\u20131.10) and for death\/major bleeding 1.18 (1.15\u20131.21), respectively. For high versus low CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc and HAS-BLED, the ORs of OAC use were 1.23 (1.15\u20131.32) and 0.20 (0.19\u20130.21), and the HRs for death\/stroke were 1.25 (1.19\u20131.30) and for death\/major bleeding 1.28 (1.21\u20131.34), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with AF and concomitant HF do not receive OAC on rational grounds. Bleeding risk inappropriately affects decision-making more than stroke risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2017-312720","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T12:20:30Z","timestamp":1516882830000},"page":"1093-1100","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure"],"prefix":"10.1136","volume":"104","author":[{"given":"Gianluigi","family":"Savarese","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Sartipy","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"},{"name":"Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Department of Medical and Health Sciences, Linkoping University, Link\u00f6ping, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"2025092004330178000_104.13.1093.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.05.001"},{"key":"2025092004330178000_104.13.1093.2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"2025092004330178000_104.13.1093.3","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267275.68538.8d"},{"key":"2025092004330178000_104.13.1093.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs314"},{"key":"2025092004330178000_104.13.1093.5","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313"},{"key":"2025092004330178000_104.13.1093.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.025"},{"key":"2025092004330178000_104.13.1093.7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ejhf.496","article-title":"Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012","volume":"18","author":"Thorvaldsen","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2025092004330178000_104.13.1093.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp175"},{"key":"2025092004330178000_104.13.1093.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.07.012"},{"key":"2025092004330178000_104.13.1093.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.07.015"},{"key":"2025092004330178000_104.13.1093.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.11.045"},{"key":"2025092004330178000_104.13.1093.12","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eun011"},{"key":"2025092004330178000_104.13.1093.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl015"},{"key":"2025092004330178000_104.13.1093.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr134"},{"key":"2025092004330178000_104.13.1093.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/601450","article-title":"Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry","volume":"2013","author":"Jespersen","year":"2013","journal-title":"Thrombosis"},{"key":"2025092004330178000_104.13.1093.16","doi-asserted-by":"crossref","first-page":"20432","DOI":"10.1038\/srep20432","article-title":"Stroke prevention in atrial fibrillation and \u2019real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey","volume":"6","author":"Potpara","year":"2016","journal-title":"Sci Rep"},{"key":"2025092004330178000_104.13.1093.17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ijcard.2016.09.086","article-title":"Atrial fibrillation and heart failure: factors influencing the choice of oral anticoagulant","volume":"227","author":"Brown","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025092004330178000_104.13.1093.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03996.x"},{"key":"2025092004330178000_104.13.1093.19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40256-015-0120-9","article-title":"International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation","volume":"15","author":"Nelson","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025092004330178000_104.13.1093.20","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afn295"},{"key":"2025092004330178000_104.13.1093.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"2025092004330178000_104.13.1093.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61233-1"},{"key":"2025092004330178000_104.13.1093.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn139"},{"key":"2025092004330178000_104.13.1093.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu359"},{"key":"2025092004330178000_104.13.1093.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn599"},{"key":"2025092004330178000_104.13.1093.26","doi-asserted-by":"crossref","unstructured":"Guo Y , Zhu H , Chen Y , et al . Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med 2017.doi:10.1016\/j.amjmed.2017.09.009","DOI":"10.1016\/j.amjmed.2017.09.009"},{"key":"2025092004330178000_104.13.1093.27","first-page":"301","article-title":"Physicians\u2019 perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation","volume":"165","author":"Bungard","year":"2001","journal-title":"CMAJ"},{"key":"2025092004330178000_104.13.1093.28","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.495036"},{"key":"2025092004330178000_104.13.1093.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38698.709572.55"},{"key":"2025092004330178000_104.13.1093.30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.amjcard.2017.07.002","article-title":"Sex and gender differences in thromboprophylactic treatment of patients with atrial fibrillation after the introduction of non-vitamin K oral anticoagulants","volume":"120","author":"Loikas","year":"2017","journal-title":"Am J Cardiol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-312720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:33:13Z","timestamp":1758367993000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-312720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":30,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2018,6,12]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/heartjnl-2017-312720"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-312720","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}